J3246 HCPCS Level II code: Injection, tirofiban hcl, 0.25 mg
J3246 is the HCPCS code for “Injection, tirofiban hcl, 0.25 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J3246Injection, tirofiban hcl, 0.25 mg
Short description: Tirofiban hcl
HCPCS · United States
Medicare details
The indicators CMS publishes with J3246 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Other drugs
- Added
- Jan 1, 2005
Where J3246 sits
- 1J codesDrugs administered other than orally
- 2Active code J3246Injection, tirofiban hcl, 0.25 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J3246 mean?
J3246 is the HCPCS code for “Injection, tirofiban hcl, 0.25 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J3246?
CMS lists J3246’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J3246
All J codesJ3230Injection, chlorpromazine hcl, up to 50 mgJ3240Injection, thyrotropin alpha, 0.9 mg, provided in 1.1 mg vialJ3241Injection, teprotumumab-trbw, 10 mgJ3243Injection, tigecycline, 1 mgJ3244Injection, tigecycline (accord), not therapeutically equivalent to j3243, 1 mgJ3245Injection, tildrakizumab, 1 mgJ3247Injection, secukinumab, intravenous, 1 mgJ3250Injection, trimethobenzamide hcl, up to 200 mgJ3260Injection, tobramycin sulfate, up to 80 mgJ3262Injection, tocilizumab, 1 mgJ3263Injection, toripalimab-tpzi, 1 mgJ3265Injection, torsemide, 10 mg/ml